Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

Health and Healthcare

Published: December 10, 2008 11:04 am

It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally you see a pattern. This month the only pattern seems to be one of no conviction either way. Here are the short seller reports in the short interest:

Stock (Ticker)                      NOV. 28    NOV. 14    CHANGE
Amgen Inc. (AMGN)             23,033,081 24,169,278 -4.70%
Celgene Corporation (CELG) 8,298,820 8,040,642    +3.21%
Biogen Idec Inc. (BIIB)          8,027,848 7,938,637    +1.12%
Genzyme Corporation (GENZ) 6,569,181 6,797,501    -3.36%
Gilead Sciences (GILD)          29,055,791 30,213,915 -3.83%

Jon C. Ogg
December 10, 2008

In 20 Years, I Haven’t Seen A Cash Back Card This Good

After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.

A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.

Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.